bax inhibitor peptide v5

Bax inhibitor peptide V5 (BIP-V5) is a Bax-mediated apoptosis inhibitor with anticancer activity.

Bax inhibitor peptide V5 acetate (Bax inhibitor peptide V5 acetate（579492-81-2 free base)) is a Bax-mediated apoptosis inhibitor, used for cancer treatment.

MLCK inhibitor peptide 18 acetate is a selective competitive inhibitor of myosin light chain kinase (IC50 = 50 nM). Displays 4000-fold selectivity over CaM kinase II and does not inhibit PKA. Cell permeable.

PKG inhibitor peptide TFA (82801-73-8 free base) is an inhibitor of ATP-competitive cGMP-dependent protein kinase (PKG).

Lyn peptide inhibitor acetate is a potent and cell-permeable inhibitor of Lyn-coupled IL-5 receptor signaling pathway, while keeping other signals intact. Lyn peptide inhibitor blocks Lyn activation and inhibits the binding of Lyn tyrosine kinase to βc subunit of IL-3/GM-CSF/IL-5 receptors. Lyn peptide inhibitor can be used for study of asthma, allergic, and other eosinophilic disorders.

SLLK, Control Peptide for TSP1 Inhibitor acetate is a control peptide for LSKL.

PKCε Inhibitor Peptide acetate is a selective PKCε inhibitor containing the site for its specific receptor for activated C kinase (RACK). PKCε Inhibitor Peptide acetate inhibits the translocation of PKCε, but not α-, β-, and δPKC.

V5 Epitope Tag Peptide acetate is a peptide

Rac1 Inhibitor F56, control peptide acetate is a control peptide version of Rac1 Inhibitor; comprises residues 45-60 of Rac1 with Trp56 replaced by Phe. Does not affect GEF-Rac1 interaction.

Thrombin Receptor Activator for Peptide 5 (TRAP-5), also known as Coagulation Factor II Receptor (1-5) or Proteinase Activated Receptor 1 (1-5), is employed in coronary heart disease (CHD) research.

Protein kinase inhibitor peptide matches the inhibitory domain of the heat-stable protein kinase inhibitor.

PKG inhibitor peptide TFA is an ATP-competitive antagonist of cGMP-dependent protein kinase (PKG), exhibiting a K_i value of 86 μM [1].

PKCε Inhibitor Scramble Peptide consists of the same amino acid sequence as the PKCε inhibitor peptide, but in a randomized order.

V5 Epitope Tag Peptide Trifluoroacetate is a Tag Peptide derived from a small Epitope on P and V proteins of monkey-virus paramyxovirus.

SLLK is a control peptide for LSKL.

PKC-ε Translocation Inhibitor Peptide is a selective modulator that controls the FcγR-mediated internalization rate of opsonized beads without affecting FcαR trafficking [1].

Selective competitive inhibitor of myosin light chain kinase (IC50 = 50 nM). Displays 4000-fold selectivity over CaM kinase II and does not inhibit PKA. Cell permeable.

Competitive inhibitor of cGMP-dependent protein kinase (PKG); analog of a substrate peptide corresponding to a phosphorylation site of histone H2B. Competes with synthetic substrates (Ki = 86 mM) but does not inhibit phosphorylation of intact histones by

The compound is a negative control peptide for the Bax inhibitor peptides V5 and P5.

PKCβII Peptide Inhibitor I, a specific PKCβII inhibitor, exhibits cardioprotective properties in a rat cardiac ischemia/reperfusion injury model and mitigates vascular endothelial dysfunction [1].

Myristoylated PKCθ pseudosubstrate peptide inhibitor is a synthetic peptide utilized to investigate the mechanism of action of protein kinase C theta (PKCθ) [1].

The recognized V5 epitope represents 95GKPIPNPLLGLDST108 of RNA polymerase α subunit of simian parain uenza virus type 5. This short peptide sequence was chosen because high-af nity antibodies can be reliably produced in many different species1.

PKCα (C2-4) inhibitor peptide is a specific antagonist to PKCα that impedes the α1A-adrenoreceptor agonist A-61603 [1] from inhibiting I_Kr.

Calpain Inhibitor V (Mu-Val-HPh-FMK) is a cell-permeable, irreversible calpain inhibitor with demonstrated anti-chlamydial activity [1].

Novel cyclic peptide that disrupts interaction between GluR6 and PSD-95

Myristoyl-MEK1 Derived Peptide Inhibitor 1, the myristoylated variant of MEK1 Derived Peptide Inhibitor 1, effectively inhibits ERK activation, demonstrating an inhibitory concentration (IC50) of 10 μM [1].

SLLK, Control Peptide for TSP1 Inhibitor (TFA) is a control peptide for LSKL, which is a Thrombospondin (TSP-1) inhibitor.

Bax BH3 peptide (55-74), wild type is a 20-amino acid peptide (Bax 1) known for its ability to induce apoptosis in various cell line models.

Human PD-L1 Inhibitor V TFA, a peptide that binds to the human PD-1 protein, exhibits a dissociation constant (Kd) of 3.32 μM and effectively inhibits the hPD-1/hPD-L1 interaction [1].

MEK1 Derived Peptide Inhibitor 1, a peptide inhibitor, prevents the in vitro activation of ERK2 by MEK1, exhibiting an inhibitory concentration (IC 50) of 30 μM. It is utilized in the study of cell-permeable [1].

Cell-permeable inhibitor of Lyn-dependent effects of the IL-5 receptor. Blocks binding of Lyn tyrosine kinase to βc subunit of IL-3/GM-CSF/IL-5 receptors, blocking Lyn activation. Inhibits IL-5 receptor-mediated eosinophil differentiation and survival in

Fibrinogen Binding Inhibitor Peptide, a synthetic dodecapeptide, represents the specific platelet receptor recognition site of the human fibrinogen g-chain (residues 400-411).

Myristoylated PKCε inhibitor peptide (Myr-PKCε-) is a cell-permeable inhibitor consisting of a peptide linked to myristic acid that specifically inhibits protein kinase C epsilon (PKCε), consequently diminishing nitric oxide (NO) release in cultured human umbilical vein endothelial cells (HUVECs) [1].

Renin Inhibitor Peptide, Rat, is a biologically active peptide that functions as a specific inhibitor of rat renin.

PDZ1 Domain Inhibitor Peptide TFA, a cyclic peptide featuring a β-Ala lactam side chain linker, specifically targets the PDZ1 domains of postsynaptic density protein 95 (PSD-95). It effectively disrupts the GluR6/PSD-95 interaction, competing against the C terminus of GluR6 for the PDZ1 domain with high efficiency [1].

Lyn Peptide Inhibitor TFA is a powerful, cell-permeable inhibitor specifically targeting the Lyn-coupled IL-5 receptor signaling pathway, without affecting alternative signaling pathways. It effectively prevents Lyn activation and impedes the association between Lyn tyrosine kinase and the βc subunit of IL-3/GM-CSF/IL-5 receptors. This compound is utilized in the investigation of asthma, allergic reactions, and various eosinophilic conditions [1].

Human PD-L1 Inhibitor V is a peptide that binds to the human PD-1 protein with an affinity characterized by a dissociation constant (Kd) of 3.32 μM, effectively inhibiting the hPD-1/hPD-L1 interaction [1].

Control peptide version of Rac1 Inhibitor; comprises residues 45-60 of Rac1 with Trp56 replaced by Phe. Does not affect GEF-Rac1 interaction.